[1]孙清林.放射性核素131I在甲亢治疗中的安全性与有效性分析[J].医学信息,2018,31(15):120-122.[doi:10.3969/j.issn.1006-1959.2018.15.038]
　SUN Qing-lin.Safety and Efficacy Analysis of Radionuclide 131I in the Treatment of Hyperthyroidism[J].Journal of Medical Information,2018,31(15):120-122.[doi:10.3969/j.issn.1006-1959.2018.15.038]
点击复制

放射性核素131I在甲亢治疗中的安全性与有效性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年15期
页码:
120-122
栏目:
药物与临床
出版日期:
2018-08-01

文章信息/Info

Title:
Safety and Efficacy Analysis of Radionuclide 131I in the Treatment of Hyperthyroidism
文章编号:
1006-1959（2018）15-0120-03
作者:
孙清林
江苏省盐城市第一人民医院核医学科，江苏 盐城 224005
Author(s):
SUN Qing-lin
Department of Nuclear Medicine,the First People's Hospital of Yancheng,Yancheng 224005,Jiangsu,China
关键词:
FT3; FT4; 131I; 甲亢; 丙硫氧嘧啶
Keywords:
Key words：FT3; FT4; 131I; Hyperthyroidism; Propylthiouracil
分类号:
R581.1
DOI:
10.3969/j.issn.1006-1959.2018.15.038
文献标志码:
A
摘要:
目的 分析放射性核素131I在甲亢治疗中的安全性与有效性。方法 回顾性分析2015年8月~2017年8月本院收治的64例甲亢患者，按照随机数字表法将其分为实验组和对照组，各32例，对照组患者给予丙硫氧嘧啶片治疗，实验组患者给予丙硫氧嘧啶片+131I治疗，观察两组患者的治疗总有效率、不良反应发生率、FT3、FT4及TSH变化水平。结果 实验组临床总有效率87.50%高于对照组的62.50%，差异有统计学意义（P＜0.05）；实验组不良反应发生率3.75%低于对照组31.25%，差异有统计学意义（P＜0.05）；治疗后，实验组患者FT3、FT4、TSH水平均优于对照组，差异有统计学意义（P＜0.05）。结论 放射性核素131I在甲亢治疗中可有效提高治疗效果，改善患者FT3、FT4及TSH水平，不良反应少。
Abstract:
Abstract：Objective To analyze the safety and efficacy of radionuclide 131I in the treatment of hyperthyroidism.Methods A retrospective analysis of 64 patients with hyperthyroidism admitted to our hospital from August 2015 to August 2017 was divided into experimental group and control group according to the random number table method,32 cases in each group.Patients in the control group were treated with propylthiouracil tablets.Patients in the experimental group were treated with propylthiouracil tablets+131I.The total effective rate,adverse reaction rate,FT3,FT4and TSH levels were observed in the two groups.Results The total effective rate of the experimental group was 87.50% higher than that of the control group 62.50%,the difference was statistically significant(P<0.05). The incidence of adverse reactions in the experimental group was 3.75% lower than that in the control group 31.25%,the difference was statistically significant(P<0.05);After treatment,the FT3,FT4,and TSH levels in the experimental group were better than those in the control group,and the difference was statistically significant(P<0.05).Conclusion Radionuclide 131I can effectively improve the therapeutic effect in the treatment of hyperthyroidism,improve the levels of FT3,FT4 and TSH in patients with less adverse reactions.

参考文献/References:

[1]万芳,林秋玉,赵红光,等.131I治疗甲状腺功能亢进症的研究进展[J].吉林大学学报(医学版),2013,39(04):851-854.
[2]徐智军,于鹏,梁英魁,等.放射性核素131I在甲亢治疗中的安全性与有效性[J].现代生物医学进展,2017,17(19):3762-3764.
[3]吴茜,王荣福.放射性核素131I在甲亢治疗中的应用现状和进展[J].标记免疫分析与临床,2015,22(01):66-68.
[4]周俐.放射性核素131I治疗甲亢的临床分析[J].中外医疗,2013,32(27):95,97.
[5]邱刚,李娜,马珊珊,等.放射性核素治疗148例老年甲亢疗效观察[J].中国实用医药,2013,8(16):39-40.
[6]魏雁.放射性核素131I治疗老年甲状腺机能亢进症前加用碳酸锂的疗效观察[J].中国中医药咨讯,2011,03(1):271-271.
[7]刘宇佳.放射性核素碘131治疗甲亢的临床分析[J].中国医药指南,2017,15(34):35-36.
[8]李明锐.131I治疗老年甲状腺功能亢进性心脏病的临床疗效评价[J].医学信息,2014,27(35):248.
[9]马新春,易小平,吴静.放射性核素碘治疗对甲亢性心脏病患者血浆ET、TNF-α及IL-1水平的影响[J].现代生物医学进展,2010,10(6):1124-1126.
[10]覃坚.放射性131碘在老年人甲亢治疗中的临床研究[J].中外医疗,2015,5(17):21-22.

相似文献/References:

[1]金 凤,肖 萌.血管性痴呆合并甲状腺功能减退发生率的研究[J].医学信息,2018,31(21):106.[doi:10.3969/j.issn.1006-1959.2018.21.029]
　JIN Feng,XIAO Meng.Study on the Incidence of Vascular Dementia Complicated with Hypothyroidism[J].Journal of Medical Information,2018,31(15):106.[doi:10.3969/j.issn.1006-1959.2018.21.029]

更新日期/Last Update: 2018-08-01